Rooted in science, prooven in market. 

Advancing innovative pharmaceuticals through groundbreaking drug delivery technologies.

Find out more

Latest report

Report archive

Latest press releases

7 May 2026 at 17:00 – Regulatory – General Meeting

Report from Orexo AB’s annual general meeting May 7 2026

All press releases

AmorphOX® in numbers

0

Years of experience with next-generation drug delivey technolgy AmorphOX®

0

AmorphOX-based formulations under research

0

Clinical trials with AmorphOX® technology

0

Patents granted and submitted

Three decades of innovation in drug delivery & product development

1995

Orexo is founded in Uppsala, Sweden, as a drug delivery company. Development begins based on first-generation drug delivery technology – the sublingual platform

2000

Diabact® UBT, for diagnosing Helicobacter pylori, receives first market approval and is commercialized through a partner

2008

Abstral®, for breakthrough cancer pain, launches in its first market via partnership

2009

Edluar®, for insomnia, achieves first market approval and is commercialized through partnership

2013

Zubsolv®, the third product based on the sublingual platform, is approved by the FDA for the treatment of opioid addiction. Orexo establishes a US subsidiary for commercialization

2016

Zubsolv in the US surpasses SEK 1 billion in gross sales

2017

Research into an overdose rescue medication started, leading to the development of next-generation drug delivery technology - AmorphOX®

2021

Pipeline expands with three clinical-phase programs and several preclinical projects all leveraging AmorphOX technology

2024

Clinical expansion in the development of a powder-based nasal anaphylaxis product. In parallel, Orexo expands research in peptides and vaccines.

2025

Orexo divests all rights to Zubsolv in the US, unlocking resources to accelerate development programs

News

Want to find out about more events? Visit our Media section.

Media

Technology

AmorphOX is powering tomorrow’s treatments

AmorphOX® is a powder-based drug delivery technology that stabilizes amorphous materials—such as peptides and biologics—and is designed to support strong bioavailability, enabling next-generation drug development.

Pipeline

Development programs

AmorphOX technology is the backbone in Orexo's development programs in both clinical and preclinical development phases.

Manufacturing

Scalable supply chain for partnership and growth

A scalable, commercial-ready supply chain for powder-based medicines, enabling faster pathways to market.

Partnership

Partner with us

We power partners´ proprietary projects with the AmorphOX® technology.

Media

Stay informed

Insights, stories, press releases and reports – all in one place. Stay connected by subscribing or following us.

Investors

Nasdaq Stockholm listing

Since 2005, Orexo is listed on Nasdaq Stockholm main list under the ticker symbol ORX. Explore our investor information.

Orexo is committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, environment and anti-corruption. Read more on www.unglobalcompact.org.